Opinion: Some kids in pain need opioids. For doctors, that means walking a tightrope
As a physician who works in a pediatric emergency department, I see the downsides of…
Author: STAT
STAT Plus: FDA claims Zantac does not form a carcinogen in patients, but says some pills should be recalled
After running simulated testing, the Food and Drug Administration says it has not found evidence…
STAT Plus: 5 burning questions about Google’s Fitbit acquisition — and its implications for health and privacy
SAN FRANCISCO — Google parent company Alphabet’s move to buy Fitbit, announced Friday, comes with…
Trump will nominate MD Anderson’s Stephen Hahn to lead FDA today
WASHINGTON — President Trump will announce his intent to nominate Dr. Stephen Hahn to lead…
STAT Plus: Pharmalittle: Pharma keeps slashing jobs in the U.S.; overseas plants have more data integrity violations
Rise and shine, everyone, another busy day is on the way. Remember, there are meetings…
Second Ebola vaccine set to be used soon in Democratic Republic of the Congo
The Democratic Republic of the Congo will begin using a second Ebola vaccine as early…
Opinion: The health information exchange has evolved from hunter and gatherer to cultivator
“Data is the new oil,” British data scientist Clive Humby once said. “It’s valuable, but…
Opinion: The EMR has changed the doctor-patient duet into a ménage-à-trois
You would have thought that my hospital was preparing for the imminent coming of the…
STAT Plus: Bill Gates spends billions on global health. With Alzheimer’s, his science adviser says, money is not the issue
WASHINGTON — He’s one of the richest men in the world. He’s sought to eradicate…
.jpg)
Social connections first, science second: How biotech’s recipe for success has its limits
When Laura Indolfi set out to launch a biotech in Boston, she had an idea…
Massachusetts General Hospital oversaw trial that led to the first death from a fecal transplant, a new paper shows
This spring, a 73-year-old man with a rare blood condition became the first person to…
STAT Plus: Pharmalittle: FDA places hold on Novartis trial for gene therapy; FDA floats plan for combating shortages
Good morning, everyone, and welcome to the middle of the week. You made it this…
STAT Plus: Democrats ‘continue to have concerns’ about FDA program to streamline regulation of medical software
A trio of Democrats on the Senate health committee, led by presidential candidate Elizabeth Warren…
Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns
The Food and Drug Administration has halted a clinical trial of Novartis’ Zolgensma gene therapy…
After big gains, Cystic Fibrosis Foundation bankrolls research toward cures — and drugs for those left out
Last week, the cystic fibrosis community celebrated the approval of a new drug from Vertex…
Opinion: The ‘cancer growing in cancer medicine’: pharma money paid to doctors
Americans are rightly furious about the high and unsustainable price of cancer drugs, which now…
Opinion: Medicare’s Shared Savings Program results should have made headlines. It got a ‘collective shrug’ instead
Like the proverbial tree falling in the forest, if the Centers for Medicare and Medicaid…
The fireman of global health: The WHO’s emergencies chief is put to the test
GENEVA — Walk into Mike Ryan’s office here on the orderly campus of the World Health…
STAT Plus: Can a simple eye exam replace costly and invasive Alzheimer’s diagnostic procedures?
Could a simple eye exam detect signs of Alzheimer’s disease? Researchers at Massachusetts General Hospital…
STAT Plus: Pharmalittle: Rise in drug costs for large employers slows; experimental TB vaccine proves effective
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Opinion: Realizing the promise of prescription digital therapeutics
Smartphones and tablets have transformed almost every facet of our daily lives, making it nearly…
‘Dear Evan Hansen’ tells a fictional story of suicide. But its actors field messages from very real people in crisis
Alex Boniello knew the kind of fan mail he might get when he joined the…
Opinion: STAT Plus: Early price setting, other market access planning is key for early-stage drug, device companies
Planning for the launch of a new drug or medical device usually includes conversations about…
STAT Plus: Mirati takes a turn at the podium with a first look at its KRAS-blocking cancer drug
A pill from Mirati Therapeutics developed to block the “undruggable” cancer protein called KRAS showed…
STAT Plus: Will an FDA panel recommend a drug for preventing premature births remain available?
A controversial treatment for preventing premature births will be reviewed by a Food and Drug…
STAT Plus: Pharmalittle: Congress struggles with drug pricing bill; in Utah, pleas on social media for insulin
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding
A California biotech announced itself to the world on Monday with $275 million, a familiar…
Opinion: It’s time for Canada to embrace universal pharmacare and protect drug coverage from corporate erosion
President Trump recently unveiled an executive order — originally titled “Protecting Medicare from Socialist Destruction”…
Opinion: Vaping and prescription opioids: limbic capitalism in action
Have you ever written something and sent it off, only to encounter a perfect example…
Medicine may work better if your doctor seems to believe it will work, new study suggests
A doctor’s subtle facial cues — an encouraging smile, or perhaps a wince — can…
Democrats’ new logic on drug pricing: Developing slightly fewer medicines is OK if it means lower prices
WASHINGTON — Democratic lawmakers in recent weeks have begun to advance an argument long seen…
More kids should get weight-loss surgery, even some preteens, pediatricians say
Even some severely obese preteens should be considered for weight loss surgery, according to new…
STAT Plus: Two patient charities settle allegations of helping drug makers pay Medicare kickbacks
Two patient assistance charities paid a total of $6 million to settle allegations of violating…
STAT Plus: Gilead faces an antitrust complaint in Brazil over hepatitis C pricing
Several advocacy groups have filed a complaint with antitrust authorities in Brazil, alleging Gilead charged…
STAT Plus: Pharmalittle: Democratic drug pricing bill may be unconstitutional; FTC staff OKs Roche deal to buy Spark
And so, another working week will soon draw to a close. Not a moment too…
An Alzheimer’s patient on what was lost when Biogen shut down its trial, and what may be gained again
Biogen’s decision to revisit a once-failed treatment for Alzheimer’s disease came as a shock to…
Opinion: The resurgence of tuberculosis is behavioral, not medical. Nudges can fix it
Nancy had been coughing for months. When she started experiencing chest pain, this bubbly mother…
STAT Plus: Nonpartisan congressional report suggests Pelosi’s drug pricing bill could be found unconstitutional
WASHINGTON — House Democrats’ signature drug pricing legislation could run afoul of not one, not…
Smaller, lighter, cheaper: A serial entrepreneur wants his portable MRI to transform medicine
GUILFORD, Conn. — In a nondescript building in this seaside town sits a prototype that…
Listen: Every angle on Biogen’s shocking Alzheimer’s news
What exactly is Biogen doing? When is a press release worth $12 billion? And what…
STAT Plus: Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock
Cel-Sci (CVM) chief executive Geert Kersten used a public letter to shareholders Thursday to express…
STAT Plus: Pharmalittle: States push back on opioid deal; sheriffs acted as front group to decry importation
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
After years of battling, Vertex and the U.K. reach a deal for cystic fibrosis medicines
After years of frustration, Vertex Pharmaceuticals struck a deal with the U.K. government to supply…
STAT Plus: Despite warnings, many U.K. clinical trial sponsors still fail to report their results
On the eve of a Parliamentary committee hearing on clinical trial reporting, a new analysis…
Opinion: New diagnostic tools are essential in the battle against antibiotic resistance
A century ago, a severe bacterial infection was often a death sentence. With the advent…
Discovered in the valley of the one-eyed lambs, a toxic weed fuels a cancer-drug gold rush — and a quandary
PHILADELPHIA — The search began immediately after breakfast. It was Sunday, the last morning of…
Opinion: San Francisco’s Mission Bay life science sector: pivoting with the times
Twenty years ago, San Francisco’s Mission Bay was an industrial zone filled with shipyards and…
STAT Plus: Blood test maker Guardant enters race for liquid biopsy with colon cancer study
A Silicon Valley company being closely watched in the race to develop liquid biopsies said…
STAT Plus: Pharmalittle: Biogen Alzheimer’s drug revival sparks skepticism; docs chide blood-thinner recommendations
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: The country’s only diabetes-focused venture fund brings on a new partner
The only type 1 diabetes-focused venture firm has a new dealmaker. Dr. Steven St. Peter…